Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
1.3
USD
|
-0.76%
|
|
-2.99%
|
-38.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
340.5
|
1,425
|
639.1
|
91.02
|
103
|
68.04
|
-
|
-
|
Enterprise Value (EV)
1 |
212.2
|
1,231
|
406.9
|
-76.63
|
37.13
|
50.45
|
-39.06
|
8.304
|
P/E ratio
|
-7.84
x
|
-30.5
x
|
-9.58
x
|
-0.8
x
|
-0.93
x
|
-0.92
x
|
-0.97
x
|
-1.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.22
x
|
18.1
x
|
7.47
x
|
1.4
x
|
1.4
x
|
0.88
x
|
0.8
x
|
0.59
x
|
EV / Revenue
|
3.25
x
|
15.7
x
|
4.76
x
|
-1.18
x
|
0.51
x
|
0.66
x
|
-0.46
x
|
0.07
x
|
EV / EBITDA
|
-12
x
|
-33.8
x
|
-6.86
x
|
0.72
x
|
-0.38
x
|
-0.68
x
|
0.52
x
|
-0.11
x
|
EV / FCF
|
-
|
-26,826,314
x
|
-4,967,778
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.19
x
|
7.34
x
|
2.07
x
|
0.42
x
|
0.82
x
|
0.86
x
|
0.92
x
|
1.43
x
|
Nbr of stocks (in thousands)
|
31,234
|
38,933
|
44,784
|
45,971
|
49,031
|
51,939
|
-
|
-
|
Reference price
2 |
10.90
|
36.61
|
14.27
|
1.980
|
2.100
|
1.300
|
1.300
|
1.300
|
Announcement Date
|
3/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
65.21
|
78.65
|
85.49
|
65.05
|
73.48
|
76.96
|
84.8
|
114.4
|
EBITDA
1 |
-17.67
|
-36.39
|
-59.34
|
-107.1
|
-98.64
|
-74.5
|
-75.75
|
-77.05
|
EBIT
1 |
-22.42
|
-42.15
|
-65.35
|
-115.5
|
-109.9
|
-80.55
|
-75.05
|
-64.43
|
Operating Margin
|
-34.38%
|
-53.59%
|
-76.44%
|
-177.61%
|
-149.61%
|
-104.66%
|
-88.5%
|
-56.31%
|
Earnings before Tax (EBT)
1 |
-25.08
|
-41.22
|
-65.21
|
-113.3
|
-108.2
|
-72.66
|
-72.9
|
-62.2
|
Net income
1 |
-25.08
|
-41.28
|
-65.23
|
-113.3
|
-108.3
|
-72.69
|
-72.92
|
-62.2
|
Net margin
|
-38.47%
|
-52.49%
|
-76.29%
|
-174.2%
|
-147.38%
|
-94.45%
|
-85.99%
|
-54.36%
|
EPS
2 |
-1.390
|
-1.200
|
-1.490
|
-2.480
|
-2.250
|
-1.410
|
-1.335
|
-0.9375
|
Free Cash Flow
|
-
|
-45.9
|
-81.91
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-58.36%
|
-95.81%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
20.68
|
15.23
|
18.24
|
14.86
|
16.72
|
18.86
|
16.7
|
18.25
|
19.76
|
19.52
|
19.27
|
18.68
|
19.44
|
17.12
|
20.04
|
EBITDA
1 |
-18.62
|
-26.53
|
-26.06
|
-25.38
|
-29.13
|
-27.04
|
-22.5
|
-22.47
|
-21.06
|
-16.04
|
-19
|
-21.1
|
-21.15
|
-
|
-
|
EBIT
1 |
-20.22
|
-28.31
|
-27.88
|
-27.26
|
-32.08
|
-29.82
|
-25.35
|
-25.23
|
-23.97
|
-18.88
|
-19.89
|
-20.81
|
-20.9
|
-21.5
|
-19
|
Operating Margin
|
-97.79%
|
-185.89%
|
-152.86%
|
-183.46%
|
-191.87%
|
-158.14%
|
-151.78%
|
-138.26%
|
-121.29%
|
-96.7%
|
-103.25%
|
-111.44%
|
-107.49%
|
-125.58%
|
-94.83%
|
Earnings before Tax (EBT)
1 |
-20.2
|
-28.2
|
-27.53
|
-26.48
|
-31.06
|
-28.64
|
-23.92
|
-29.07
|
-26.58
|
-12.96
|
-19.27
|
-20.25
|
-20.32
|
-20.8
|
-18.4
|
Net income
1 |
-20.2
|
-28.21
|
-27.55
|
-26.49
|
-31.07
|
-28.66
|
-23.96
|
-29.1
|
-26.58
|
-12.97
|
-19.27
|
-20.25
|
-20.32
|
-20.8
|
-18.4
|
Net margin
|
-97.66%
|
-185.26%
|
-151.02%
|
-178.3%
|
-185.79%
|
-151.96%
|
-143.45%
|
-159.47%
|
-134.5%
|
-66.42%
|
-100.03%
|
-108.44%
|
-104.51%
|
-121.5%
|
-91.84%
|
EPS
2 |
-0.4500
|
-0.6300
|
-0.6000
|
-0.5800
|
-0.6700
|
-0.6100
|
-0.5000
|
-0.6000
|
-0.5400
|
-0.2600
|
-0.3733
|
-0.3917
|
-0.3883
|
-0.3750
|
-0.3375
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/23/23
|
5/3/23
|
8/8/23
|
11/7/23
|
2/28/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
128
|
194
|
232
|
168
|
65.8
|
17.6
|
107
|
59.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-45.9
|
-81.9
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-27.4%
|
-25.8%
|
-42.9%
|
-62.3%
|
-69.5%
|
-69%
|
-52.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.410
|
4.990
|
6.910
|
4.670
|
2.560
|
1.510
|
1.410
|
0.9100
|
Cash Flow per Share
|
-1.000
|
-1.240
|
-1.610
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
3.25
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
4.13%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/28/24
|
-
|
-
|
-
|
Average target price
4.6
USD Spread / Average Target +253.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.10% | 68.04M | | +43.36% | 58.06B | | -5.31% | 40.53B | | +37.52% | 38.99B | | +14.75% | 26.7B | | -12.56% | 26.56B | | -22.45% | 18.98B | | +0.04% | 12.17B | | +25.12% | 12B | | +26.04% | 11.92B |
Other Biotechnology & Medical Research
|